Search Results for keywords:"National Cancer Institute"

The National Cancer Institute has announced a change to the schedule of the Special Emphasis Panel meeting on clinical and translational cancer research. Originally scheduled to end at 7 p.m. on February 5, 2025, the meeting will now conclude earlier, at 2 p.m. The meeting, held from February 4-5, 2025, will take place at the National Cancer Institute in Rockville, Maryland, and will remain closed to the public.

The National Cancer Institute is holding several meetings to discuss grant applications and contract proposals. These meetings will be closed to the public to protect confidential information, such as trade secrets and personal data. The meetings will take place in March and May 2021 at the National Cancer Institute in Rockville, Maryland, using telephone conference calls. Contact information for the scientific review officers in charge of each meeting is provided for those needing further details.

The National Cancer Institute has announced a closed meeting to take place on May 9, 2025. This meeting, part of the Federal Advisory Committee Act, will review and evaluate contract proposals and will be held virtually. Confidentiality will be maintained to protect sensitive trade secrets and personal privacy. The session will run from 9:00 a.m. to 6:00 p.m., and any inquiries can be directed to Shamala K. Srinivas, Ph.D.

The National Cancer Institute, part of the National Institutes of Health, announced a series of closed virtual meetings in June 2025. These meetings, held by special emphasis panels, are intended to review and evaluate grant applications related to cancer research. They will be closed to the public to protect confidential information and personal privacy. Meeting details, including dates, times, and contact information for scientific review officers, are provided for each committee session.

The National Cancer Institute announced that it will hold two closed meetings in March 2025 to discuss and evaluate grant applications. The meetings will not be open to the public because they might involve discussing confidential information like trade secrets and personal data. Both meetings will be held virtually from the National Cancer Institute in Rockville, Maryland. The meetings aim to focus on different aspects of cancer research, including clinical and translational research, and biospecimen science approaches.

The National Cancer Institute is considering granting an exclusive patent license to Senti Bio for developing and commercializing certain therapies that target CD33-expressing cancers. These therapies involve using specially engineered immune cells, like T cells and NK cells, to recognize and attack cancer cells marked by the CD33 protein, commonly found in acute myeloid leukemia. People interested in this license must submit their comments or applications by January 29, 2021. The patent rights involved have been assigned to the U.S. government, and the license could apply worldwide.

The National Cancer Institute has announced upcoming meetings focused on reviewing and evaluating grant applications, set to take place virtually on April 10-11, 2025. These meetings will be closed to the public to protect confidential information and personal privacy. They involve the National Cancer Institute Special Emphasis Panel, which aims to explore innovative technologies for cancer research. Interested parties can contact Jeffrey E. DeClue, the Scientific Review Officer, for further information.

The National Cancer Institute Council of Research Advocates is holding a virtual meeting open to the public on March 10-11, 2021, from 12:00 p.m. to 3:00 p.m. The agenda includes welcome and remarks from the Chairwoman, updates from the NCI, legislative updates, and a director's update. Those interested in attending and requiring special accommodations should contact Amy Williams at the National Cancer Institute. Additional information and the meeting agenda will be available on the NCI's dedicated advisory webpage.

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Kyverna Therapeutics. This license would allow Kyverna to use certain patented inventions to develop a therapy using chimeric antigen receptors (CAR) targeting CD19 for treating autoimmune diseases. The CAR technology uses CRISPR/Cas9-edited T cells to recognize and attack cells expressing the CD19 protein, potentially offering a new treatment option for diseases such as lupus nephritis. Comments or objections to this proposed license must be submitted by March 5, 2021.

The National Cancer Institute announced closed meetings for a committee focusing on diet, lipid metabolism, and cancer. These meetings will be held on April 8, 2025, from 9:30 a.m. to 3:00 p.m. The meetings are virtual and not open to the public to protect confidential information and personal privacy. The meeting will review and evaluate grant applications related to cancer research, and the contact person is Dr. Shree Ram Singh.